Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.61 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.47 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199942 | 1.00 | ALDH1A1 (0.66) | ALDH1A1TSHRTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL4199938 | 1.00 | ALDH1A1 (0.66) | ALDH1A1TSHRTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL15830554 | 0.86 | PRMT5 (0.59) | ALDH1A1TSHRTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL27028578 | 0.85 | CHRNB4 (0.58) | ALDH1A1SMN1; SMN2CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL12661586 | 0.83 | CHRNB4 (0.53) | ALDH1A1TSHRTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL9814621 | 0.83 | CHRNB2 (0.50) | ALDH1A1TSHRTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL466047 | 0.83 | CHRNB4 (0.53) | ALDH1A1TSHRTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL1073697 | 0.83 | CHRNB4 (0.53) | ALDH1A1TSHRTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL4826477 | 0.82 | CHRNB2 (0.64) | TSHRCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL7611507 | 0.81 | ALDH1A1 (0.61) | ALDH1A1TSHRTP53CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2009-01-22 | — | — | US | disclosed |
| US-7388020-B2 | Benzimidazol derivatives modulate chemokine receptors | ASTRAZENECA AB (SE) | 2008-06-17 | — | — | US | disclosed |
| US-7375136-B2 | pH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375136-B2 | pH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375136-B2 | pH-dependent NMDA receptor antagonists | EMORY UNIVERSITY (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1499590-B8 | Piperidine derivatives as potassium channel blockers | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| EP-1499590-B1 | Piperidine derivatives as potassium channel blockers | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1436258-A4 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | UNIV EMORY (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1499590-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | disclosed |
| EP-1436258-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | Emory University (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040116435-A1 | Benzimidazol derivatives modulate chemokine receptors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| EP-1373248-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003051839-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2002074763-A9 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002074763-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002072542-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023791-A1 | PH-dependent NMDA receptor antagonists | GRIN1, GRIA4, GRIA1 | ALDH1A1 2194/4885TSHR 2036/4885TP53 1444/4885 |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | GRIN1, GRIN2B, GRIN3A | ALDH1A1 2602/4885TSHR 833/4885TP53 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.